Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06612632
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-14
Brief Title:
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Umbrella Study to Evaluate the Safety and Preliminary Efficacy of Combined or Sequential Immunotherapy in Patients with Advanced Solid Tumors Progressing on Clinical Trial Drugs
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study plans to include approximately 60-100 patients with advanced solid tumors who have progressed on clinical trial drugs It will use an open-label single-arm multi-cohort umbrella design In the first phase patients who have progressed during treatment with novel tumor immunotherapy drugs will initially be targeted combining or sequencing with PD-1 monoclonal antibody therapy The inclusion criteria for frontline clinical trials are as follows priority will be given to phase I clinical trials of novel immunotherapeutics as monotherapy such as tumor vaccines NK cell therapy and new immune checkpoint inhibitors Based on preliminary data these have shown synergistic effects with PD-1L1 monoclonal antibodies In principle the same investigational drug will only be used in either a combination or sequencing cohort Subsequently the study will expand to include patients who have progressed on other clinical trial treatments combining or sequencing with other immune mechanism drugs
Detailed Description:
This study plans to include approximately 60-100 patients with advanced solid tumors who have progressed on clinical trial drugs using an open-label single-arm multi-cohort umbrella design In the first phase patients who have progressed during treatment with novel tumor immunotherapy drugs will initially be targeted combining or sequencing with PD-1 monoclonal antibody therapy The selection criteria for frontline clinical trials are as follows priority will be given to phase I clinical trials of novel immunotherapeutics as monotherapy such as tumor vaccines NK cell therapy and new immune checkpoint inhibitors Based on preliminary data these have shown synergistic effects with PD-1L1 monoclonal antibodies In principle the same investigational drug will only be used in either a combination or sequencing cohort Subsequently the study will expand to include patients who have progressed on other clinical trial treatments combining or sequencing with other immune mechanism drugs
Based on the interventions the study is divided into combination therapy cohorts sequential therapy cohorts and real-world cohorts The combination therapy cohorts will be further subdivided according to the investigational drug the patients received in the frontline setting for instance patients who have progressed on investigational drug A eg SG1827 will receive drug A combined with PD-1 monoclonal antibody therapy cohort A and patients who have progressed on investigational drug B eg ABO2011 will receive drug B combined with PD-1 monoclonal antibody therapy cohort B and so on In the sequential therapy cohorts regardless of the investigational drug used in the frontline setting patients will receive PD-1 monoclonal antibody therapy The real-world cohorts will include patients who do not meet the inclusion criteria for the aforementioned cohorts or refuse to participate in the interventional trials with only subsequent treatment information tumor progression and overall survival being collected
No specific sample size is predetermined for each cohort and the study team may adjust the cohort sizes based on preliminary study results In the combination therapy cohorts the dosage and administration method of the investigational drugs will continue as per the patients previous trial treatments In both the combination and sequential therapy cohorts the PD-1 monoclonal antibody will be administered at a fixed dose of 200 mg every 21 days or 3 mgkg every 14 days The treatments will continue until disease progression death or the occurrence of intolerable toxicity
Based on the interventions the study is divided into combination therapy cohorts sequential therapy cohorts and real-world cohorts The combination therapy cohorts will be further subdivided according to the investigational drug the patients received in the frontline setting for instance patients who have progressed on investigational drug A eg SG1827 will receive drug A combined with PD-1 monoclonal antibody therapy cohort A and patients who have progressed on investigational drug B eg ABO2011 will receive drug B combined with PD-1 monoclonal antibody therapy cohort B and so on In the sequential therapy cohorts regardless of the investigational drug used in the frontline setting patients will receive PD-1 monoclonal antibody therapy The real-world cohorts will include patients who do not meet the inclusion criteria for the aforementioned cohorts or refuse to participate in the interventional trials with only subsequent treatment information tumor progression and overall survival being collected
No specific sample size is predetermined for each cohort and the study team may adjust the cohort sizes based on preliminary study results In the combination therapy cohorts the dosage and administration method of the investigational drugs will continue as per the patients previous trial treatments In both the combination and sequential therapy cohorts the PD-1 monoclonal antibody will be administered at a fixed dose of 200 mg every 21 days or 3 mgkg every 14 days The treatments will continue until disease progression death or the occurrence of intolerable toxicity
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None